Skip to main content

Table 1 Baseline patient characteristics by indigenous status at enrolment to the Australian HIV observational database

From: Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)

  Non-indigenous Indigenous Total
(n = 2155) (n = 42) (N = 2197)
  n % n % n %
Gender       
Female 100 4.6 5 11.9 105 4.8
Male 2051 95.2 36 85.7 2087 95.0
Transgender 4 0.2 1 2.4 5 0.2
Reported HIV exposure category       
Blood products 10 0.5 0 0.00 10 0.5
Heterosexual 170 7.9 8 19.1 178 8.1
IDU 51 2.4 3 7.1 54 2.5
MSM 1812 84.1 28 66.7 1840 83.8
MSM & IDU 60 2.8 1 2.4 61 2.8
Other 24 1.1 1 2.4 25 1.1
missing 28 1.3 1 2.4 29 1.3
Prior AIDS-defining condition       
No 1777 82.5 38 90.5 1815 82.6
Yes 378 17.5 4 9.5 382 17.4
Geographical location of enrolling clinic      
Metropolitan 1777 82.5 21 50.0 1798 81.8
Non-metropolitan 378 17.5 21 50.0 399 19.2
Antiretroviral therapy at enrolment       
Naïve 562 26.1 14 33.3 576 26.2
Prior, not current, therapy 395 18.3 2 4.8 397 18.1
Current mono/dual therapy 76 3.5 1 2.4 77 3.5
3+ II,+/−NRTI,+/−NNRTI,+/−PI 16 0.7 0 0.0 100 4.6
3+ NNRTI + PI,+/−NRTI, No II 96 4.5 1 2.4 485 22.1
3+ NRTI + NNRTI, No PI, No II 545 25.3 13 31.0 562 25.6
3+ NRTI + PI, No NNRTI, No II 426 19.8 7 16.7 433 19.7
3+ NRTI, No PI, No NNRTI, No II 39 1.8 4 9.5 43 2.0
CD4 count at enrolment (cells per mm3)     
<200 199 9.2 3 7.1 202 9.2
200-299 214 9.9 6 14.3 220 10.0
300-499 650 30.2 13 31.0 663 30.2
500+ 989 45.9 18 42.9 1007 45.8
Missing 103 4.8 2 4.8 105 4.8
HIV viral load at enrolment (copies/ml))      
≤400 1245 57.8 25 59.5 1270 57.8
401-10,000 339 15.7 5 11.9 344 15.7
>10,000 470 21.8 10 23.8 480 21.8
Missing 101 4.7 2 4.8 103 4.7
  1. NRTI Nucleoside or nucleotide reverse transcriptase inhibitor, PI Protease inhibitor, NNRTI Non-nucleoside reverse transcriptase inhibitor, II Integrase inhibitor